Expanding local vaccine production in South Africa

Context

Currently, the African continent is able to produce only one per cent of the vaccines it needs. Local production is essential to reduce its dependence on imports. The conditions in South Africa are favourable for this, as it has a well-developed industry, a well-trained workforce and a high level of research expertise.

But South Africa’s Government requires support to prevent pandemics and ensure that everyone has access to the vaccinations and pharmaceutical products they need.

Objective

Access to high-quality vaccines for all population groups is improved in South Africa.

Approach

The project is receiving financial support from the European Union (EU). It is working with the South African Department of Health (NDoH) to introduce and implement an immunisation programme for adults. This will enable South Africa to improve its response to pandemics and build preparedness capabilities, making it better equipped to tackle future health emergencies.

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the project promotes the state regulation of vaccines and medicines in order to ensure safe, high-quality South African health products. GFA Consulting Group is implementing measures for SAHPRA to enable the organisation to achieve the World Health Organization's highest possible level for the approval of medicines. In particular, the project is providing advice on digital solutions to make work processes effective.

Together with the Department of Science and Innovation (DSI), the project is putting in place training courses with businesses, universities and state research institutes. This builds local capacities to develop and produce vaccines in South Africa.

The project is also expanding international and intra-continental exchange with the aim of producing the bulk of vaccines for Africa in Africa, while providing advice on planning regional procurement mechanisms.

Last update: September 2024